Deutsche Bank Downgrades DaVita HealthCare Partners to Hold (DVA)
DaVita HealthCare Partners (NYSE:DVA) was downgraded by Deutsche Bank from a “buy” rating to a “hold” rating in a research note issued on Friday, TheFlyOnTheWall.com reports. They currently have a $77.00 target price on the stock. Deutsche Bank’s target price points to a potential upside of 5.34% from the company’s current price.
A number of other firms have also recently commented on DVA. Analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Friday, August 1st. They now have a $74.00 price target on the stock. Separately, analysts at Raymond James downgraded shares of DaVita HealthCare Partners from an “outperform” rating to a “market perform” rating in a research note on Monday, July 21st. They now have a $75.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $75.33.
In other DaVita HealthCare Partners news, Insider Jeanine Marie Jiganti sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $72.14, for a total transaction of $180,350.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of DaVita HealthCare Partners (NYSE:DVA) traded down 0.85% during mid-day trading on Friday, hitting $72.48. The stock had a trading volume of 102,935 shares. DaVita HealthCare Partners has a 1-year low of $52.75 and a 1-year high of $74.84. The stock has a 50-day moving average of $72.34 and a 200-day moving average of $69.34. The company has a market cap of $15.569 billion and a P/E ratio of 23.14.
DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Thursday, July 31st. The company reported $0.95 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.89 by $0.06. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.10 billion. During the same quarter in the prior year, the company posted $1.84 earnings per share. The company’s quarterly revenue was up 10.5% on a year-over-year basis. On average, analysts predict that DaVita HealthCare Partners will post $3.62 EPS for the current fiscal year.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.